Syndax signals expanding Revuforj market share and targets $10B addressable opportunity while ramping Niktimvo
Source: SeekingAlpha
2026-02-26 22:48:23 ET
More on Syndax Pharmaceuticals
- Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
- Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
- Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Syndax Pharmaceuticals GAAP EPS of -$0.78 misses by $0.23, revenue of $68.7M beats by $3.95M
- Syndax Pharmaceuticals Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Syndax signals expanding Revuforj market share and targets $10B addressable opportunity while ramping Niktimvo
Syndax Pharmaceuticals Inc.
NASDAQ: SNDX
SNDX Trading
15.19% G/L:
$24.72 Last:
1,081,335 Volume:
$22.53 Open:
SNDX Latest News
February 26, 2026 04:01:00 pm
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SNDX Stock Data
$1,884,313,688
83,351,330
1.17%
104
N/A
Biotechnology & Life Sciences
Healthcare
US
NEW YORK
